32 results about "Microvascular complication" patented technology

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient's diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

The present invention relates to a method for treating one or more diabetic microvascular complications in a patient in need of said treatment comprising: (a) diagnosing the severity of at least three different microvascular complications in said patient by calculating a diabetes microvascular complications score with a diabetes microvascular complications scoring tool; and (b) administering to said patient in need thereof a therapeutic amount of a compound selected from the group consisting of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine and pegaptanib, or a pharmaceutically acceptable salt thereof, and ranibizumab; in an amount that is effective in treating one or more diabetic microvascular complications in said diabetic patient.

A novel herbal formulation for the prevention and management of diabetes mellitus and its significance in the prevention of diabetic micro-vascular complications. A novel herbal formulation for the prevention of endothelial dysfunction Diabetes Mellitus and Diabetic Micro-Vascular complications comprising: Salacia chinensis and at least one other active constituent selected from Coccinia indica and Hippophae rhamnoides and optionally additives in trace amounts.

The present invention relates to the use of IL-6 or a fragment, variant, fusion protein, functional derivative or salt thereof in microvascular complications.

Disclosed herein are compositions and methods for the identification of a subject at risk for developing microvascular complications associated with diabetes such as diabetic nephropathy and diabetic retinopathy. Also disclosed is a therapeutic target for the prevention and treatment of microvascular complications associated with diabetes.

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout; dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications,.macrovascular complications, lipid disorders, prediabetes., obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.

The present invention provides pharmaceutical compositions which can achieve good state of glycemic control and correct postprandial hyperglycemia and early morning fasting hyperglycemia. The present pharmaceutical composition is for administration before meal to prevent or inhibit the progression of diabetic complication, which comprises 5 to 45 mg, as a single dose, of mitiglinide or a pharmaceutically acceptable salt thereof, or a hydrate thereof (for example, mitiglinide calcium salt hydrate). And said compositions are extremely useful for prevention or inhibition of progression of, for example, diabetic microvascular complications and arteriosclerotic diseases, because the frequency of adverse drug reactions such as hypoglycemic symptoms and gastrointestinal disorders is low.

The invention relates to a drug for adjusting glucose and lipid metabolism disorders and treating diabetes and chronic vascular complications thereof and a preparing method of the drug, and belongs tothe field of traditional Chinese medicine. The drug is prepared from, by weight, 3-9 parts of radix astragali, 3-9 parts of rhizoma polygonati, 2-6 parts of cortex lycii radicis and 2-6 parts of cortex moutan. The preparing method of the drug comprises the steps of a, weighing the radix astragali, rhizoma polygonati, cortex lycii radicis and cortex moutan separately according to the weight ratioof (3-9):(3-9):(2-6):(2-6) for use; b, conducting water extraction and alcohol precipitation or certain-concentration ethyl alcohol backflow on the medicinal materials separately, and then conductingconcentrating to obtain an extract; c, adding the extract into an ingredient, and conducting processing and shaping. The drug has the functions of tonifying qi and nourishing yin, clearing heat and activating blood, and has outstanding curative effects of treating the type-2 diabetes glucose and lipid metabolism disorders and the chronic microvascular complications thereof.

The invention relates to compounds of natural origin and their pharmaceutically acceptable and active mixture to decrease glucose, cholesterol, uric acid, and body fat the high levels, cytoprotection of damaged organs, activation of metabolism and cell proliferation. It is exemplified with the pharmaceutical composition comprising a pharmaceutically effective amount of the compounds of Formulation I, and its method on in vitro and in vivo systems. Formulation I and its variables can be used to treat hyperglycemia, gout, dyslipidemia, obesity, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, pre-diabetes, arrhythmias, myocardial infarction, renal and pancreatic complications, cardiovascular complications.

The invention relates to a natural medicine extract composite for suppressing the formation of end-stage glycosylation final products and application thereof. In particular, the composite is prepared by taking an active element extract with the function of suppressing the formation of the end-stage glycosylation final products in four natural plants including plantain, root of kudzuvine, cornel and turmeric as raw materials through optimized proportion and combination. The extract medicine can efficiently prevent and suppress diabetes microvascular complications and the development of heart, brain blood vessel atherosclerosis caused by the end-stage glycosylation final products.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute hypertension or malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.

The present invention is directed to a method of treating microvascular complications associated with diabetes and age-related macular degeneration. The methods include administering to an animal in need thereof an effective amount of a composition, wherein the composition is selected from the group consisting of kallistatin, fragments of kallistatin, analogs or derivatives of kallistatin, and combinations thereof.

Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.

Pathological retinal neovascularization is a common micro-vascular complication in several retinal diseases including retinopathy of prematurity (ROP), diabetic retinopathy, age-related macular degeneration and central vein occlusion. Disclosed herein are compositions and methods useful for the treatment or prevention of retinal neovascularization and related diseases in a subject in need thereof. Exemplary methods include administering a composition including PEGylated arginase 1 to a subject in need thereof to promote reparative angiogenesis and decrease retinal neovascularization in the eye.

A medicinal preparation for treating diabetes and a preparation method thereof belong to the technical field of Chinese patent medicines. Including components are: Coptis chinensis, Trichosanthes, Chinese yam and other traditional Chinese medicines, acetylsalicylic acid, and glibenclamide. Extract Coptis chinensis into berberine, grind trichosanthum powder, yam and Yu Liren, decoct and concentrate other medicines to form a paste, mix all the obtained products, dry them, and crush them, then add acetylsalicylic acid powder and glibenclamide powder, and mix well , to obtain a powder; then subdivide into capsules to obtain a capsule. The pharmaceutical preparation for treating diabetes of the present invention has the effects of lowering blood sugar, eliminating urine sugar, promoting the repair and regeneration of pancreatic beta cells, preventing the occurrence of complications in the nervous system and microvascular system, improving and protecting liver and kidney functions, and reducing cholesterol and triglycerides .

The invention discloses a diabetic microangiopathy gene susceptibility detection kit and a group of SNP (Single Nucleotide Polymorphism) loci applied by the kit, the group of SNP loci comprises 11 SNP loci related to diabetic retinopathy and 12 SNP loci related to diabetic nephropathy, and the invention also discloses amplification primer sequences and single-base extension primer sequences corresponding to 22 SNP loci. A diabetic microangiopathy gene susceptibility detection kit composed of the amplification primer sequence and a single-base extension primer sequence is used for rapidly, effectively and accurately predicting the genetic susceptibility of microangiopathy of a subject and evaluating the onset risk of microvascular complications of diabetic patients. And follow-up visit and early intervention and early guidance of high-risk patients are facilitated.

The present invention relates to a medicine for regulating glucose and lipid metabolism disorder for treating diabetes and its chronic vascular complications, and a preparation method of the medicine, belonging to the field of traditional Chinese medicine. It is prepared from the following raw materials in parts by weight: 3-9 parts of Astragalus, 3-9 parts of Polygonatum, 2-6 parts of Digupi and 2-6 parts of Danpi. The preparation method of the medicine comprises: a) according to weight ratio 3-9:3-9:2-6; Ethanol precipitation or reflux of ethanol with a certain concentration, concentration, and extract; c) adding auxiliary materials to the extract, and processing and forming. The medicine of the invention has the effects of nourishing qi and nourishing yin, clearing away heat and activating blood circulation, and has outstanding curative effect for treating type 2 diabetes mellitus glucose and lipid metabolism disorder and its chronic microvascular complications.

The invention discloses salvia miltiorrhiza bunge tea and a preparation method thereof. The salvia miltiorrhiza bunge tea is composed of the following raw materials in parts by weight: 200-210 parts of salvia miltiorrhiza bunge, 18-20 parts of peanut oil, 12-15 parts of tenualosa reevesii meat, 18-20 parts of a baked pancake, 4-5 parts of lard stearin, 8-10 parts of bertholletia excelsa, 7-9 parts of pisum sativum, 4-6 parts of chrysanthemum coronarium, 6-7 parts of bamboo funguses, 14-17 parts of mulberry juice, 8-9 parts of fermented glutinous rice, 1-2 parts of sophora japonica branches, 1-2 parts of siberian elm barks, 1-2 parts of American ginsengs, 1-2 parts of ailanthus altissima swingle, 1-2 parts of hovenia acerba lindl, a proper amount of water and 15-20 parts of a nutritional addition agent. The salvia miltiorrhiza bunge tea takes salvia miltiorrhiza bunge as a main material, has the effects of invigorating the circulation of blood, unblocking the meridian and relieving pains, clearing away the heart-fire and relieving restlessness, and cooling blood and eliminating carbuncles, can be used for preventing and treating diabetic microangiopathy, and has treating effect on many types of hyperviscositemia; and added traditional Chinese medicines have the effects of reducing fever and promoting diuresis, relieving a cough and relieving restlessness, dispelling the effects of alcohol, and invigorating stomach and enriching blood.

The invention relates to compounds of Formula I:and its pharmaceutical acceptable salts, solvates, enantiomers, stereoisomers and hydrates thereof. Compounds of Formula I and and compositions comprising Formula I are used to treat patients with metabolic syndrome and may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral administration, as a syrup, or for injection. More specifically, compounds and compositions of Formula I may be used to treatment of acute hypertension or-malignant hypertension, hypoglycemia in disease states such as insulinoma (a tumor producing insulin) or congenital hyperinsulinism, hyperuricemia, gout, dyslipidemia, obesity, urea cycle disorders, hyperglycemia, insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia and cardiovascular complications.

Described herein are compounds of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, for use in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver; diabetic complications such as macro (ischemic heart disease, cerebrovascular disease and peripheral vascular disease) and micro (cataract, retinopathy nephropathy neuropathy, maculopathy and glaucoma) vascular complication; and cardiovascular diseases such as atherosclerosis, restenosis, hypertension, vasospasm, and cardiac hypertrophy; and lung disorders and lung fibrosis.

The invention discloses new application of astaxanthin, and particularly relates to application of the astaxanthin to preparation of an aldose reductase inhibitor. According to application, the astaxanthin serves as one of active components or the only active component for preparing the aldose reductase inhibitor. The inventor finds that the astaxanthin has a significant inhibitory effect on aldose reductase, the aldose reductase is a key rate-limiting enzyme of a polyol pathway, activation of the polyol pathway is an important reason for occurrence and development of diabetic microvascular complications, the astaxanthin can inhibit activation of the polyol pathway by inhibiting the activity of the aldose reductase, and then generation of the diabetic complications is reduced; and the astaxanthin does not generate side effects, can be applied to preparation of drugs for treatment or prevention of the diabetic complications, and can also be applied to preparation of health care productsfor adjuvant treatment of the diabetic complications.

The invention provides a dietary supplement formula of using nutrition supplementary food for diabetic microvascular complication and a method. The invention is characterized in that: a food formula for supplementing nutrition every day comprises Shutang high calcium electuary, which is taken twice and two bags each day, capsule of mycelium of cultured cordyceps sinensis, which is taken twice and altogether 8 ones, and spirulina capsule, which is taken three times and altogether 18 ones. Based on the formula and the method provided in the invention, satisfactory effects on a variety of symptoms of diabetic microvascular complication are achieved after constant supplement for continuous 60 to 90 days. The active effects of the invention are as follows: supplemented nutritional components, mineral matters and trace elements are targeted; the health care functions of hypoxia tolerance, antioxidation and immunoloregulation are obtained; the health care function of adjusting blood sugar is realized; the health care function of immunoloregulation and antifatigue are achieved.

The present invention relates generally to the field of hyperglycemia-induced complications. More particularly, it concerns methods and compositions for the treatment and prevention of microvascular complications associated with diabetes. In one embodiment, the present invention provides a method of inhibiting hyperglycemia-induced platelet activation in a subject by administering to the subject an effective amount of a TRPC6 inhibitor.

The invention relates to the compounds of formula (I) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof The pharmaceutical compositions comprising an effective amount of compounds of formula (I), and methods for the treatment of hyperglycemia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of insulin resistance, diabetes mellitus, diabetes insipidus, type 1 diabetes, type 2 diabetes, microvascular complications, macrovascular complications, lipid disorders, prediabetes, obesity, arrhythmia, myocardial infarction, stroke, neuropathy, renal complications, hypertriglyceridemia, cardiovascular complications, and post prandial hyperglycemia.